Market research
TILS.LSE Tiziana Life Sciences PLC
LSE GBP Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 57M
- P/E ratio
- Not available
- Analyst target
- 500
- Dividend yield
- 0.0%
- Beta
- -0.02
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BKWNZY55
- Market cap
- 57M
- P/E ratio
- Not available
- Analyst target
- 500
- Dividend yield
- 0.0%
- Beta
- -0.02
About
About Tiziana Life Sciences PLC
Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.
Research context
Tiziana Life Sciences PLC appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TILS.LSE discussion.
5 years, 6 months ago
Tiziana Life Sciences PLC is currently in a long term downtrend where the price is trading 32.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Tiziana Life Sciences PLC gets an overall score of 1/5.